225 related articles for article (PubMed ID: 24153039)
1. [State of the art in nuclear imaging for the diagnosis of bone metastases].
Ouvrier MJ; Vignot S; Thariat J
Bull Cancer; 2013 Nov; 100(11):1115-24. PubMed ID: 24153039
[TBL] [Abstract][Full Text] [Related]
2. Positron emission tomography and bone metastases.
Fogelman I; Cook G; Israel O; Van der Wall H
Semin Nucl Med; 2005 Apr; 35(2):135-42. PubMed ID: 15765376
[TBL] [Abstract][Full Text] [Related]
3. Miscellaneous cancers (lung, thyroid, renal cancer, myeloma, and neuroendocrine tumors): role of SPECT and PET in imaging bone metastases.
Chua S; Gnanasegaran G; Cook GJ
Semin Nucl Med; 2009 Nov; 39(6):416-30. PubMed ID: 19801221
[TBL] [Abstract][Full Text] [Related]
4. Comparison of 18F-FDG PET and bone scintigraphy in detection of bone metastases of thyroid cancer.
Ito S; Kato K; Ikeda M; Iwano S; Makino N; Tadokoro M; Abe S; Nakano S; Nishino M; Ishigaki T; Naganawa S
J Nucl Med; 2007 Jun; 48(6):889-95. PubMed ID: 17504877
[TBL] [Abstract][Full Text] [Related]
5. 18F-fluoride PET used for treatment monitoring of systemic cancer therapy: results from the National Oncologic PET Registry.
Hillner BE; Siegel BA; Hanna L; Duan F; Quinn B; Shields AF
J Nucl Med; 2015 Feb; 56(2):222-8. PubMed ID: 25593113
[TBL] [Abstract][Full Text] [Related]
6. 18F-FDG PET/CT is a prognostic biomarker in patients affected by bone metastases from breast cancer in comparison with 18F-NaF PET/CT.
Piccardo A; Puntoni M; Morbelli S; Massollo M; Bongioanni F; Paparo F; Altrinetti V; Gonella R; Gennari A; Iacozzi M; Sambuceti G; DeCensi A
Nuklearmedizin; 2015; 54(4):163-72. PubMed ID: 26165806
[TBL] [Abstract][Full Text] [Related]
7. Prospective Comparison of 99mTc-MDP Scintigraphy, Combined 18F-NaF and 18F-FDG PET/CT, and Whole-Body MRI in Patients with Breast and Prostate Cancer.
Minamimoto R; Loening A; Jamali M; Barkhodari A; Mosci C; Jackson T; Obara P; Taviani V; Gambhir SS; Vasanawala S; Iagaru A
J Nucl Med; 2015 Dec; 56(12):1862-8. PubMed ID: 26405167
[TBL] [Abstract][Full Text] [Related]
8. Sensitivity in detecting osseous lesions depends on anatomic localization: planar bone scintigraphy versus 18F PET.
Schirrmeister H; Guhlmann A; Elsner K; Kotzerke J; Glatting G; Rentschler M; Neumaier B; Träger H; Nüssle K; Reske SN
J Nucl Med; 1999 Oct; 40(10):1623-9. PubMed ID: 10520701
[TBL] [Abstract][Full Text] [Related]
9. The role of fluorodeoxyglucose, 18F-dihydroxyphenylalanine, 18F-choline, and 18F-fluoride in bone imaging with emphasis on prostate and breast.
Langsteger W; Heinisch M; Fogelman I
Semin Nucl Med; 2006 Jan; 36(1):73-92. PubMed ID: 16356797
[TBL] [Abstract][Full Text] [Related]
10. Bone metastases diagnosis possibilities in studies with the use of 18F-NaF and 18F-FDG.
Tarnawska-Pierścińska M; Hołody Ł; Braziewicz J; Królicki L
Nucl Med Rev Cent East Eur; 2011; 14(2):105-8. PubMed ID: 22219151
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of Prostate Cancer Bone Metastases with 18F-NaF and 18F-Fluorocholine PET/CT.
Beheshti M; Rezaee A; Geinitz H; Loidl W; Pirich C; Langsteger W
J Nucl Med; 2016 Oct; 57(Suppl 3):55S-60S. PubMed ID: 27694173
[No Abstract] [Full Text] [Related]
12. Lung Metastasis From Prostate Cancer Revealed by 18F-FDG PET/CT Without Osseous Metastasis on Bone Scan.
Su HY; Chen ML; Hsieh PJ; Hsieh TS; Chao IM
Clin Nucl Med; 2016 May; 41(5):392-3. PubMed ID: 26859201
[TBL] [Abstract][Full Text] [Related]
13. Detection of bone metastases in thyroid cancer patients: bone scintigraphy or 18F-FDG PET?
Phan HT; Jager PL; Plukker JT; Wolffenbuttel BH; Dierckx RA; Links TP
Nucl Med Commun; 2007 Aug; 28(8):597-602. PubMed ID: 17625381
[TBL] [Abstract][Full Text] [Related]
14. (18)F-fluoride PET imaging in a nude rat model of bone metastasis from breast cancer: Comparison with (18)F-FDG and bioluminescence imaging.
Kang WJ; Song EH; Park JY; Park YJ; Cho A; Song HT
Nucl Med Biol; 2015 Sep; 42(9):728-33. PubMed ID: 26068116
[TBL] [Abstract][Full Text] [Related]
15. Comparing whole body (18)F-2-deoxyglucose positron emission tomography and technetium-99m methylene diphosphonate bone scan to detect bone metastases in patients with breast cancer.
Yang SN; Liang JA; Lin FJ; Kao CH; Lin CC; Lee CC
J Cancer Res Clin Oncol; 2002 Jun; 128(6):325-8. PubMed ID: 12073051
[TBL] [Abstract][Full Text] [Related]
16. Impact of Pretreatment Combined (18)F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography Staging on Radiation Therapy Treatment Decisions in Locally Advanced Breast Cancer.
Ng SP; David S; Alamgeer M; Ganju V
Int J Radiat Oncol Biol Phys; 2015 Sep; 93(1):111-7. PubMed ID: 26279029
[TBL] [Abstract][Full Text] [Related]
17. Comparison and discrepancy of 18F-2-deoxyglucose positron emission tomography and Tc-99m MDP bone scan to detect bone metastases.
Kao CH; Hsieh JF; Tsai SC; Ho YJ; Yen RF
Anticancer Res; 2000; 20(3B):2189-92. PubMed ID: 10928175
[TBL] [Abstract][Full Text] [Related]
18. Complimentary role of FDG-PET imaging and skeletal scintigraphy in the evaluation of patients of prostate carcinoma.
Tiwari BP; Jangra S; Nair N; Tongaonkar HB; Basu S
Indian J Cancer; 2010; 47(4):385-90. PubMed ID: 21131750
[TBL] [Abstract][Full Text] [Related]
19. [Heterogeneity of bone metastases in a patient with breast cancer: case report illustrating the potential of combining various imaging techniques].
Withofs N; Collignon J; Rorive A; Jerusalem G; Hustinx R
Rev Med Liege; 2011; 66(5-6):288-90. PubMed ID: 21826964
[TBL] [Abstract][Full Text] [Related]
20. Meta-analysis: comparison of F-18 fluorodeoxyglucose-positron emission tomography and bone scintigraphy in the detection of bone metastasis in patients with lung cancer.
Chang MC; Chen JH; Liang JA; Lin CC; Yang KT; Cheng KY; Yeh JJ; Kao CH
Acad Radiol; 2012 Mar; 19(3):349-57. PubMed ID: 22173321
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
